Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Dermatologic 1

Conditions

Lung Neoplasms 10Carcinoma, Non-Small-Cell Lung 9Fallopian Tube Neoplasms 7Ovarian Neoplasms 6Colorectal Neoplasms 5Urinary Bladder Neoplasms 4Pancreatic Neoplasms 4Melanoma 4Carcinoma, Hepatocellular 4Lymphoma, Large B-Cell, Diffuse 3Glioblastoma 3Colonic Neoplasms 3Carcinoma, Renal Cell 3Brain Neoplasms 3Urethral Neoplasms 2Ureteral Neoplasms 2Thyroid Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Rectal Neoplasms 2Prostatic Neoplasms 2Neoplasm Metastasis 2Nasopharyngeal Carcinoma 2Multiple Myeloma 2Lymphoid Interstitial Pneumonia 2Leukemia, Lymphocytic, Chronic, B-Cell 2Carcinoma, Neuroendocrine 2Carcinoma 2Burkitt Lymphoma 2Brenner Tumor 2Breast Neoplasms 2

Interventions

Infliximab 2vedolizumab 1Prednisone 1Methylprednisolone Hemisuccinate 1Methylprednisolone 1LDP-02 1Immunoglobulin G 1Disulfides 1CT-P13 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Colitis × Disulfides × Clear all
NCT04407247 2025-12-23

Infliximab or Vedolizumab in Treating Immune Checkpoint Inhibitor-Related Colitis in Patients With Genitourinary Cancer or Melanoma

M.D. Anderson Cancer Center

Phase 1/2 Active not recruiting
47 enrolled
DermatologicThoracic

Carcinoma, Non-Small-Cell Lung, Colitis, Melanoma, Urogenital Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡